Ivonescimab beats Imfinzi in Chinese biliary tract cancer trial
Summit Therapeutics (Nasdaq: SMMT) and its Chinese partner Akeso (HKG: 9926) have reported the first Phase III success for bispecific antibody ivonescimab outside lung cancer, after the drug extended survival in previously untreated advanced biliary tract cancer.
The HARMONi-GI1 study, sponsored and run by Akeso in China, tested ivonescimab plus chemotherapy against AstraZeneca's Imfinzi (durvalumab) on the same gemcitabine and cisplatin backbone. It enrolled around 680 patients with unresectable, locally advanced or metastatic disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze